New hope for blood cancer patients when first treatment stops working
NCT ID NCT07024706
Summary
This study is testing whether a combination of two targeted drugs (acalabrutinib and venetoclax) can effectively treat patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) when their cancer returns after successful first-line treatment. The trial will enroll 80 adults whose cancer relapsed at least 2 years after completing their initial therapy. Researchers will group patients by disease risk and measure how well the treatment works and how safe it is over up to 5 years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL LYMPHOCYTIC LYMPHOMA (SLL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
Boston, Massachusetts, 02215, United States
-
Research Site
Charlotte, North Carolina, 28204, United States
-
Research Site
Durham, North Carolina, 27705, United States
-
Research Site
Horn, 3580, Austria
-
Research Site
Brno, 625 00, Czechia
-
Research Site
Hradec Kralova, 50005, Czechia
-
Research Site
Ostrava, 708 502, Czechia
-
Research Site
Dublin, 7, Ireland
-
Research Site
Dublin, D08 NHY1, Ireland
-
Research Site
Lugo, 48022, Italy
-
Research Site
Meldola, 47014, Italy
-
Research Site
Milan, 20162, Italy
-
Research Site
Padua, 35128, Italy
-
Research Site
Roma, 00165, Italy
-
Research Site
Rome, 00168, Italy
-
Research Site
Torino, 10126, Italy
-
Research Site
Bydgoszcz, 85-168, Poland
-
Research Site
Krakow, 30-727, Poland
-
Research Site
Lodz, 93-513, Poland
-
Research Site
Lublin, 20-090, Poland
-
Research Site
Warsaw, 02-172, Poland
-
Research Site
Warsaw, 02-776, Poland
-
Research Site
Barcelona, 08041, Spain
-
Research Site
Barcelona, 8035, Spain
-
Research Site
Granada, 18014, Spain
-
Research Site
Madrid, 28031, Spain
-
Research Site
Madrid, 28034, Spain
-
Research Site
Madrid, 28041, Spain
-
Research Site
Majadahonda, 28222, Spain
Conditions
Explore the condition pages connected to this study.